Peripheral blood c-erbB-2 expression by reverse transcriptase-polymerase chain reaction in breast cancer patients receiving chemotherapy

Clinical Breast Cancer

Volumn 3, Issue 3, 2002, Pages 201-205

  Fonseca, Fernando L A ^a   Soares, Heloisa P ^a   Manhani, Ana Rita ^a   Bendit, Israel ^a   Novaes, Mafalda ^a   Zatta, Simone M ^a   Arias, Vitor ^b   Pinhal, Maria Aparecida S ^a   Weinschenker, Patrícia ^a   Del Giglio, Auro ^a  

^a FACULDADE DE MEDICINA DO ABC   (Brazil)

^b INSTITUTO ADOLFO LUTZ   (Brazil)

Author keywords

Minimal residual disease; Molecular diagnosis; Molecular marker

Indexed keywords

ANTINEOPLASTIC AGENT; CK 19 PROTEIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; ONCOPROTEIN; PACLITAXEL; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD; BREAST CANCER; CANCER PATIENT; CANCER STAGING; CELL STRAIN MCF 7; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOPEROXIDASE STAINING; MINIMAL RESIDUAL DISEASE; MONONUCLEAR CELL; ONCOGENE C ERB; RACE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0036695668     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2002.n.024     Document Type: Article

References (20)

1. Datta YH, Adams PT, Drobyski WR, et al. Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J Clin Oncol 1994; 2:475-482.
2. Schoenfeld A, Kruger KH, Gomm J, et al. The detection of micrometastases in the peripheral blood and bone marrow of patients with breast cancer using immunohistochemistry and reverse transcriptase polymerase chain reaction for keratin 19. Eur J Cancer 1997; 33:854-861.
3. Moscinski LC, Trudeau WL, Fields KK, et al. High-sensitivity detection of minimal residual breast carcinoma using the polymerase chain reaction and primers for cytokeratin 19. Diagn Mol Pathol 1996; 5:173-180.
4. Fields KK, Elfebein GJ, Trudeau WL, et al. Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. J Clin Oncol 1996; 14:1868-1876.
5. Vannucchi AM, Bosi A, Glinz S, et al. Evaluation of breast tumor cell contamination in the bone marrow and leukapheresis collections by RT-PCR for cytokeratin-19 mRNA. Br J Haem 1998; 103:610-617.
6. Manhani AR, Manhani R, Soares HP, et al. CK-19 expression by RT-PCR in the peripheral blood of breast cancer patients correlates with response to chemotherapy. Breast Cancer Res Treat 2001; 66:249-254.
7. Zach O, Kasparu H, Krieger O, et al. Detection of circulation mammary carcinoma cells in the peripheral blood of breast cancer patients via a nested reverse transcriptase polymerase chain reaction assay for mammaglobin mRNA. J Clin Oncol 1999; 17:2015-2019.
8. Leitzel K, Lieu B, Curley E, et al. Detection of cancer cells in peripheral blood of breast cancer patients using reverse transcription-polymerase chain reaction for epidermal growth factor receptor. Clin Cancer Res 1998; 4:3037-3043.
9. Wasserman L, Dreilinger A, Easter D, et al. A seminested RT-PCR assay for HER2/neu: initial validation of a new method for the detection of disseminated breast cancer cells. Mol Diagn 1999; 4:21-28.
10. Hung MC, Lau YK. Basic science of HER-2/neu: A review. Semin Oncol 1999; 26 (suppl 12):51-59.
11. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:1132-1139.
12. Slamon DJ, Godolphin W, Jones LA, et al. Studies of HER-2/neu protooncogene in human breast and ovarian cancer. Science 1989; 244:707-712.
13. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-792.
14. Vogel C, Cobleigh M, Tripathy D, et al. First-line, single-agent Herceptin® (trastuzumab) in metastatic breast cancer. a preliminary report. Eur J Cancer 2001; 37 (suppl 1):25-29.
15. Smith I. Future directions in the adjuvant treatment of breast cancer: the role of trastuzumab. Ann Oncol 2001; 12 (suppl 1):S75-S79.
16. Novaes M, Bendit I, Garicochea B, et al. Reverse transcriptase-polymerase chain reaction analysis of cytokeratin 19 expression in the peripheral blood mononuclear cells of normal female blood donors. Mol Pathol 1997; 50:209-211.
17. Krismann M, Todt B, Schroder J, et al. Low specificity of cytokeratin 19 reverse transcriptase-polymerase chain reaction analyses for detection of hematogenous lung cancer dissemination. J Clin Oncol 1995; 13:2769-2775.
18. Gluck S, Ross AA, Layton TJ, et al. Decrease in tumor cell contamination and progenitor cell yield in leukapheresis products after consecutive cycles of chemotherapy for breast cancer treatment. Biol Blood Marrow Transplant 1997; 3:316-323.
19. Schulze R, Schulze M, Wischnik A, et al. Tumor cell contamination of peripheral blood stem cell transplants and bone marrow in high-risk breast cancer patients. Bone Marrow Transplant 1997; 19:1223-1228.
20. Smith BM, Slade MJ, English J, et al. Response of circulating tumor cells to systemic therapy in patients with metastatic breast cancer: comparison of quantitative polymerase chain reaction and immunocytochemical techniques. J Clin Oncol 2000; 18:1432-1439.